Daewoong Pharmaceutical Co., Ltd (069620.KS)
- Previous Close
158,300.00 - Open
159,700.00 - Bid 157,500.00 x --
- Ask 157,600.00 x --
- Day's Range
155,200.00 - 161,700.00 - 52 Week Range
100,100.00 - 171,600.00 - Volume
22,076 - Avg. Volume
36,978 - Market Cap (intraday)
1.817T - Beta (5Y Monthly) 0.59
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 7, 2025 - Aug 11, 2025
- Forward Dividend & Yield 600.00 (0.38%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
201,875.00
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. Daewoong Pharmaceutical Co., Ltd. has a collaboration agreement with Salipro Biotech AB for the use of Salipro platform for stabilizing challenging membrane proteins to advance drug discovery. The company was founded in 1945 and is headquartered in Seoul, South Korea.develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. Daewoong Pharmaceutical Co., Ltd. has a collaboration agreement with Salipro Biotech AB for the use of Salipro platform for stabilizing challenging membrane proteins to advance drug discovery. The company was founded in 1945 and is headquartered in Seoul, South Korea.
www.daewoong.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 069620.KS
View morePerformance Overview: 069620.KS
Trailing total returns as of 6/16/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare to: 069620.KS
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: 069620.KS
View moreValuation Measures
Market Cap
1.82T
Enterprise Value
2.38T
Trailing P/E
47.32
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.26
Price/Book (mrq)
2.26
Enterprise Value/Revenue
1.65
Enterprise Value/EBITDA
19.07
Financial Highlights
Profitability and Income Statement
Profit Margin
2.67%
Return on Assets (ttm)
5.08%
Return on Equity (ttm)
3.78%
Revenue (ttm)
1.44T
Net Income Avi to Common (ttm)
38.48B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
102.86B
Total Debt/Equity (mrq)
75.43%
Levered Free Cash Flow (ttm)
-157.19B